Medicines for Malaria Venture and Novartis announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
24 April 2024
Positive data from the phase II/III CALINA study, part of the EDCTP-funded PAMAfrica consortium, demonstrated that a novel formulation of Coartem® (artemether-lumefantrine) developed for babies weighing less than 5kg has the required pharmacokinetic profile and good efficacy and safety to treat malaria in this vulnerable group. The data, which will be presented at the MIM 2024 symposium ‘Grassroots Mobilization to End Malaria: Integrating the care of the young infant’ on 26 April, have been submitted for regulatory review.
“The CALINA trial is an example of the type of Europe-Africa collaboration we need to close malaria treatment gaps for vulnerable groups, and EDCTP is proud to be part of this endeavor. ”
Pauline Beattie, Operations Manager and Scientific Advisor, EDCTP Association
More information
- Read the full press release
- Read more about the CALINA trial
- Read more about the PAMAfrica consortium